In a report released on March 2, David Risinger from Leerink Partners maintained a Hold rating on Amgen (AMGN – Research Report). The company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback